Q-omics provides the consensus-scored CALHM1 profile across patient tissues and cancer cell-line models. CALHM1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, CALHM1 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, CALHM1 RNA expression shows 12,319 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and COAD as cancer lineages where CALHM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CALHM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CALHM1 survival associations across molecular data types. CALHM1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CALHM1 RNA expression–survival associations across cancer types. High CALHM1 expression shows unfavorable associations in UVM, KIRP, KIRC, DLBC and LIHC, but favorable associations in SKCM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for CALHM1 RNA expression.
This table summarizes CALHM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CALHM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CALHM1 shows lower tumor expression in COAD and KICH and higher tumor expression in BRCA, HNSC, THCA and ESCA. The COAD box plot shows higher CALHM1 RNA expression in normal versus tumor tissue (log2 FC = −0.075, t-test p < 0.001).
This table shows molecular features associated with CALHM1 in patient tissues and cancer cell lines. In patient samples, CALHM1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CALHM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and SOFT_TISSUE.
